Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
3/21/23 | Altimmune (ALT) | Pemvidutide for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
3/21/23 | Altimmune (ALT) | Pemvidutide for Diabetes Mellitus, Type II | Subscribers Only | Subscribers Only | Subscribers Only |
3/20/23 | Biogen (BIIB) | Tofersen for Amyotrophic Lateral Sclerosis (ALS) | Subscribers Only | Subscribers Only | Subscribers Only |
3/16/23 | Astellas Pharma (4503:JP) | Xtandi for Prostate Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
3/16/23 | Pfizer (PFE) | Paxlovid for COVID-19 Treatment | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
03/22/23 | Subscribers Only | Subscribers Only | Trial Data - Top-Line Results |
03/22/23 | Subscribers Only | Subscribers Only | Trial Announcement - Trial Completion |
03/22/23 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
03/22/23 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
03/22/23 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |